Publications by authors named "H Vermaat"
Article Synopsis
- Vulvar lichen sclerosus (LS) is a chronic inflammatory condition that can lead to serious complications like differentiated vulvar intraepithelial neoplasia (dVIN) and vulvar squamous cell carcinoma (VSCC), making its management critical especially post-surgery for VSCC.
- A survey of 44 gynecologic oncologists in the Netherlands revealed that topical corticosteroids (TCS) are prescribed more frequently for LS patients without a history of VSCC compared to those following surgery for VSCC (86% vs. 52%).
- Both patient groups are primarily treated with ultra-potent TCS for symptom relief and to prevent progression to serious conditions, though guidelines on post-surgery LS management remain unclear.
Introduction: Lichen sclerosis (LS) is a chronic inflammatory skin disease, mostly affecting the anogenital region. Patients with LS have a higher risk of developing anogenital squamous cell carcinoma (SCC), although exact numbers are not known.
Objective: To systematically review the absolute risk (AR) and incidence rate (IR) of developing SCC in patients with anogenital LS, as well as patient characteristics that influence the risk of developing LS associated SCC.
Background: In patients with vulval or anogenital dermatitis, irritant contact dermatitis is more common than allergic contact dermatitis. The reported frequency and relevance of contact sensitivity in anogenital dermatitis varies greatly.
Objective: To determine the frequency and relevance of contact sensitization in a Dutch group of female patients with chronic anogenital complaints.
Background: Systemic glucocorticoids (GCs) are often needed to treat dermatologic patients. The long-term use of GCs, however, is associated with potentially severe side-effects. GC-induced osteoporosis (GIO) is one of the most serious complications, but the risk of the occurrence of GIO seems to be generally underestimated.
View Article and Find Full Text PDFArticle Synopsis
- * A compound called 6-benzylthioinosine (6BT) was discovered to induce differentiation in myeloid leukemia cell lines and primary patient samples, while also causing cell death in some leukemia cell lines without harming normal cells.
- * 6BT's mechanism of action likely involves ATP depletion leading to growth inhibition and differentiation, and it shows promise by reducing tumor growth in animal models, suggesting its potential as a targeted therapy for AML.